NKGen Biotech, Inc. financial data

Symbol
NKGN, NKGNW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3001 Daimler St,, Santa Ana, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Graf Acquisition Corp. IV (to 9/29/2023)
Latest financial report
10-Q - Q3 2024 - Mar 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.44 % -80.3%
Debt-to-equity -128 % +24.6%
Return On Equity 84.1 % -83.5%
Return On Assets -306 % -197%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.9M shares +97.1%
Common Stock, Shares, Outstanding 35.7M shares +63.2%
Entity Public Float 62.8M USD -62.3%
Common Stock, Value, Issued 4K USD +100%
Weighted Average Number of Shares Outstanding, Basic 29.1M shares +117%
Weighted Average Number of Shares Outstanding, Diluted 41.3M shares +208%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Cost of Revenue 0 USD
Research and Development Expense 13.2M USD -29.3%
General and Administrative Expense 18.1M USD +39.2%
Costs and Expenses 31.3M USD -1.67%
Operating Income (Loss) -31.3M USD +15.3%
Nonoperating Income (Expense) 5.95M USD -40.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -80M USD -116%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -48.5M USD +33%
Earnings Per Share, Basic -2.37 USD/shares +65.9%
Earnings Per Share, Diluted -2.45 USD/shares +64.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8K USD -99.9%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 0 USD
Assets, Current 911K USD -91.2%
Property, Plant and Equipment, Net 13.6M USD -7.46%
Operating Lease, Right-of-Use Asset 415K USD +366%
Assets 15M USD -40.5%
Accounts Payable, Current 13.5M USD +69.5%
Employee-related Liabilities, Current 1.31M USD +78.9%
Accrued Liabilities, Current 1.02M USD -76.1%
Liabilities, Current 37.1M USD -4.45%
Deferred Income Tax Liabilities, Net 33K USD +26.9%
Operating Lease, Liability, Noncurrent 282K USD
Liabilities 62M USD -5.76%
Retained Earnings (Accumulated Deficit) -177M USD -37.7%
Stockholders' Equity Attributable to Parent -47.1M USD -15.8%
Liabilities and Equity 15M USD -40.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.03M USD +17.9%
Net Cash Provided by (Used in) Financing Activities 4.01M USD -27.9%
Net Cash Provided by (Used in) Investing Activities 35K USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 35.7M shares +63.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8K USD -98.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 237K USD -97.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 120K USD
Deferred Tax Assets, Valuation Allowance 33.7M USD +41.6%
Operating Lease, Liability 500K USD
Depreciation 800K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -48.5M USD
Lessee, Operating Lease, Liability, to be Paid 550K USD +450%
Property, Plant and Equipment, Gross 18.2M USD -0.07%
Operating Lease, Liability, Current 154K USD +60.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 249K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 242K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.22 pure +267%
Lessee, Operating Lease, Liability, to be Paid, Year Three 249K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.8M USD +27.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 551K USD +36.7%
Additional Paid in Capital 130M USD +7.78%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 295K USD -2.96%
Deferred Tax Assets, Net of Valuation Allowance 34.1M USD +39.2%
Share-based Payment Arrangement, Expense 4.23M USD +12.9%
Interest Expense 1.07M USD +3044%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%